FOLR1 and ovarian carcinoma: From a broader molecular profiling viewpoint, the key determinants for guiding personalised, nanoparticle-enabled therapy in ovarian cancer are highlighted as multi-omic profiling of BRCA/HRD, HER2, FOLR1 and other targets [111].